A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Status:
Recruiting
Trial end date:
2024-01-28
Target enrollment:
Participant gender:
Summary
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the
number of days with migraine in young people ages 12 to 17 with chronic migraine.